The global prevalence and incidence of myasthenia gravis (MG) have grown significantly in recent years, according to 70 years’ worth of data. 1 The data, published in Neuroepidemiology ...

Winnacunnet High School senior Joe Labrecque has transformed his battle with a rare chronic illness into a mission to help ...

Myasthenia gravis (MG) is a rare, chronic autoimmune disorder that disrupts the communication between nerves and muscles. It ...

Understanding side effects of therapy for myasthenia gravis and their impact on daily life. BMC Neurol. 2019;19(1):335. 8 Bubuioc A, et al. The epidemiology of myasthenia gravis. Journal of ...

The FDA has approved Johnson & Johnson's anti-FcRn antibody, nipocalimab, for the treatment of generalized myasthenia gravis. The drug will be sold under the brand name IMAAVY. This approval ...

Myasthenia gravis (MG) disrupts signals between your nerves and voluntary muscles, especially the ones that control your: Eyes or eyelids Face, jaw, and mouth Neck and throat area Arms ...

Myasthenia gravis (MG) results from autoimmune antibodies ... LRP4 disease had a higher prevalence in women; the average age ...

Autoimmune generalized myasthenia gravis is a disease that manifests ... Inebilizumab was not associated with a higher incidence of serious adverse events. This article was published on April ...